These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31153649)

  • 1. Reply to Zhipeng Mai's Letter to the Editor re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol 2019;76:98-105.
    Shah TT; Peters M; Arya M; Ahmed HU
    Eur Urol; 2019 Sep; 76(3):e63-e64. PubMed ID: 31153649
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol 2019;76:98-105.
    Mai Z
    Eur Urol; 2019 Sep; 76(3):e61-e62. PubMed ID: 31153648
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Francesco Montorsi, Armando Stabile, Elio Mazzone, Giorgio Gandaglia, and Alberto Briganti's Letter to the Editor re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Eur Urol 2022;81:407-13.
    Reddy D; Ahmed HU
    Eur Urol; 2022 Sep; 82(3):e74-e75. PubMed ID: 35690513
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Eur Urol 2022;81:407-13.
    Montorsi F; Stabile A; Mazzone E; Gandaglia G; Briganti A
    Eur Urol; 2022 Sep; 82(3):e73. PubMed ID: 35661628
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Stephanie Guillaumier, Max Peters, Manit Arya, et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol 2018;74:422-9.
    Zhou Z; Zhou Y; Yan W
    Eur Urol; 2019 Apr; 75(4):e114. PubMed ID: 30502103
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Zhipeng Mai, Weigang Yan, and Zhien Zhou's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561-70.
    Ilie G; Rutledge RDH
    Eur Urol; 2023 Aug; 84(2):e48-e49. PubMed ID: 37244817
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Runqiang Yuan and Hongxing Huang's Letter to the Editor re: Ernesto R. Cordeiro Feijoo, Arjun Sivaraman, Eric Barret, et al. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. Eur Urol 2016;69:214-20.
    Sivaraman A; Barret E
    Eur Urol; 2017 May; 71(5):e148-e149. PubMed ID: 28161029
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to John T. Leppert and James D. Brooks' Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146-54.
    Mahal BA; Yang DD; Nguyen PL
    Eur Urol; 2018 Nov; 74(5):e112-e113. PubMed ID: 30029822
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Thomas Zilli, Gilles Créhange and Olivier Chapet's Letter to the Editor re: Pascal Rischmann, Albert Gelet, Benjamin Riche, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. Eur Urol 2017;71:267-73.
    Rischmann P
    Eur Urol; 2017 Jul; 72(1):e15-e16. PubMed ID: 28089305
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Taimur T. Shah, Graeme MacLennan, Rob Pickard, Samuel McClinton and Veeru Kasivisvanathan's Letter to the Editor re: Zhangqun Ye, Guohua Zeng, Huan Yang, et al. Efficacy and Safety of Tamsulosin in Medical Expulsive Therapy for Distal Ureteral Stones with Renal Colic: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Eur Urol 2018;73:385-91.
    Ye Z; Zeng G; Chen Z; Xu H
    Eur Urol; 2018 Aug; 74(2):e45-e47. PubMed ID: 29753393
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7.
    Vickers AJ; Lilja H; Assel M
    Eur Urol; 2019 Mar; 75(3):e56. PubMed ID: 30327273
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Francesco Montorsi and Giorgio Gandaglia's Letter to the Editor re: Riccardo Autorino, Homayoun Zagar, Mirandolino B. Mariano, et al. Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-institutional Analysis. Eur Urol 2015;68:86-94; Re: Matthew Bultitude, Ben Challacombe. Simple Prostatectomy: A Step Too Far for Laparoscopy? Eur Urol 2015;68:95-6. Eur Urol 2015;68:e7-8.
    Autorino R; Zargar H; Porpiglia F
    Eur Urol; 2015 Jul; 68(1):e9-10. PubMed ID: 25666848
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to E. David Crawford and Bo-Eric Persson's letter to the editor re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026.
    Gandaglia G; Sun M; Briganti A; Karakiewicz PI
    Eur Urol; 2014 Aug; 66(2):e36-7. PubMed ID: 24746970
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91.
    van der Poel HG; van den Bergh RCN; Briers E; Cornford P; Govorov A; Henry AM; Lam TB; Mason MD; Rouvière O; De Santis M; Wiegel T; Willemse PM; van Poppel H; Mottet N
    Eur Urol; 2019 Feb; 75(2):e23-e24. PubMed ID: 30237024
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374-82.
    Glicksman RM; Berlin A
    Eur Urol; 2021 Sep; 80(3):e79-e80. PubMed ID: 34158186
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Daniela Wittmann, Ted A. Skolarus' Letter to the Editor re: Neil E. Martin, Laura Massey, Caleb Stowell, et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. Eur Urol 2014;67:460-7.
    Martin NE; Stowell C
    Eur Urol; 2016 Jun; 69(6):e127. PubMed ID: 26873843
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8.
    Vis AN; Boevé LMS
    Eur Urol; 2019 May; 75(5):e131-e132. PubMed ID: 30616950
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Pirus Ghadjar, Thomas Wiegel's Letter to the Editor re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome, Toxicity of Stereotactic Body Radiotherapy, Elective Nodal Radiotherapy. Eur Urol 2019;76:732-9.
    De Bleser E; Ost P
    Eur Urol; 2020 Mar; 77(3):e62-e63. PubMed ID: 31744645
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re: Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503-14. Improving the Methodological Quality of Prostate Cancer Core Outcome Sets in Future Updates.
    Beyer K; MacLennan S; Van Hemelrijck M
    Eur Urol; 2022 Sep; 82(3):e68-e69. PubMed ID: 35688663
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to Christian Daniel Fankhauser, Lorelei A. Mucci, and Travis A. Gerke's Letter to the Editor re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol 2017;71:907-12.
    Epstein JI; Trock B; Han M
    Eur Urol; 2017 Jul; 72(1):e11-e12. PubMed ID: 28108147
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.